Multicenter Study of Fulminant Type 1 Diabetes in China
This study took FT1D（fulminant type 1 diabetes） as the research object, collected the cases of FT1D patients, and described the clinical characteristics of this type of disease. The HLA susceptibility genes of FT1D were identified by PCR and other techniques, taking age-sex-matched healthy subjects as controls and HLA
| Condition(s) | Diabetes Mellitus, Type 1 |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study took FT1D（fulminant type 1 diabetes） as the research object, collected the cases of FT1D patients, and described the clinical characteristics of this type of disease. The HLA susceptibility genes of FT1D were identified by PCR and other techniques, taking age-sex-matched healthy subjects as controls and HLA genes as the research entry point. |
| Who can participate | patients with fulminant 1 diabetes Inclusion Criteria: 1\) diabetic ketosis or ketoacidosis occurred soon after the onset of hyperglycemic symptoms; 2) patient presented with plasma glucose ≥16.0 mmol/L and HbA1c \<8.7% at the first visit; and 3) patient had urinary C-peptide excretion \<10 µg/day,fasting serum C-peptide level \<0.10 nmol/L, or postprandial serum C-peptide \<0.17 nmol/L at onset Exclusion Criteria: Case reports of previously diagnosed with diabetes were excluded. Healthy Volunteers Inclusion Criteria: * Normal control: The inclusion criteria are as follows: (1) Oral glucose tolerance test (OGTT): fasting blood glucose (FPG) \<5.6 mmol/L and postprandial 2 h blood glucose (PPG) \<7.8 mmol/L. The participants voluntarily signed the informed consent and extracted 3ml of perip |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Second Xiangya Hospital of Central South University |
| Locations | Quanzhou, Fujian, China; Guangzhou, Guangdong, China; Nanning, Guangxi, China; Zunyi, Guangzhou, China; Haikou, Hainan, China; Changsha, Hunan, China (+4 more sites) |
| Start date | 2022-05-20 |
| NCT ID | NCT05593081 |
| Official listing | https://clinicaltrials.gov/study/NCT05593081 |